CClinicalTrials.gg
TerminatedNCT05634538Updated Jun 4, 2025Results posted

The ROB-OSTIAL Study

An interventional study of Robotic-assisted PCI with Corpath GRX® System and Standard PCI in Coronary Artery Disease, sponsored by Corindus Inc.. Terminated at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Corindus Inc. · Not applicable, Interventional, and Treatment

Why this study was terminated
Sponsor strategic decision
Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the accuracy of robotic-assisted percutaneous coronary intervention (PCI) using the CorPath GRX® System, versus standard PCI when treating ostial lesions.

CorPath GRX System (the Device) is a robotic-like device that is cleared for the remote delivery and control of heart catheterization devices. It helps doctors insert and move heart catheters (a thin, flexible tube) and similar types of devices inside patients blood vessels to treat the blockage in their heart.

The results will help to evaluate whether procedures using the CorPath GRX result in more accurate stenting (placing of a tube to keep heart vessel open) compared to standard PCI.

Read the detailed description

To assess accuracy of robotic-assisted PCI in obtaining full ostial lesion coverage and minimal protrusion compared to standard PCI.

Robotically assisted PCI offers the opportunity of performing minimal device movements (up to a minimum of 1 mm) in a stable and reproducible setting. This feature may be of great help when dealing with ostial lesions, whose treatment requires a precise stent positioning to avoid strut protrusion but also geographic miss of the lesion. Robotic-assisted PCI for ostial lesions showed encouraging results in large observational registries, but no study compared this approach with standard PCI.

The aim is to perform a randomized (1:1) study comparing standard (n=33) and robotic-assisted PCI (n=33) in obtaining full lesion coverage when treating ostial lesions (ostial left main will be excluded).

Primary endpoint of the study will be full ostial coverage as assessed by IVUS imaging, while secondary endpoints will be procedural success, vessel damage and number of protruding struts in the donor vessel as assessed by IVUS imaging.

02

Conditions studied

  • Coronary Artery Disease

Keywords

  • Ostial Lesion
  • Robotic-assisted PCI
  • PCI
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male or nonpregnant female aged ≥18 years
  • Coronary OSTIAL lesion suitable for percutaneous coronary intervention (PCI)
  • The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Cardiogenic shock or hemodynamic instability requiring support.
  • ST-elevation myocardial infarction.
  • Ongoing acute renal failure.
  • In the opinion of the investigator, the subject is deemed unsuitable for robotic PCI due to clinical status and/or anatomic characteristics
  • More than one lesion to be treated
  • Ostial left main disease
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Active comparator
    Robotic-assisted PCI with Corpath GRX® System

    Percutaneous coronary intervention (PCI) using the Corpath GRX System.

    Device: Robotic-assisted PCI with Corpath GRX® System

  • Active comparator
    Standard PCI

    Percutaneous coronary intervention (PCI) using manual techniques. This arm will be completed without robotic assistance.

    Procedure: Standard PCI

Interventions

  • DeviceRobotic-assisted PCI with Corpath GRX® System

    The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary interventions (PCI).

  • ProcedureStandard PCI

    Percutaneous coronary intervention (PCI) is a procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart. This arm will be completed without robotic assistance.

05

What researchers measure

Primary outcomes

  1. Evidence of Full Ostial Coverage at Angiographic and IVUS Assessment

    Procedure-dependent geographic miss in millimeters (mm) obtained using intravascular ultrasound (IVUS)

    Time frame: Measured at end of procedure

Secondary outcomes

  1. Distance From Most Proximal Stent Strut and Coronary Ostium (mm), as Assessed by IVUS

    Distance from most proximal stent strut and coronary ostium (mm), as assessed by IVUS

    Time frame: Measured at end of procedure

  2. Comparison of Participants With In-hospital Major Cardiovascular Events

    Time frame: Measured at discharge or 72 hours, whichever comes first

  3. Procedural Duration

    Defined as the duration from when the sheath is inserted until it is removed

    Time frame: Measured at end of procedure

  4. Major Adverse Cardiovascular Events at 1 Month Follow-up

    Time frame: Measured at 1 month

06

Results

Posted Jun 4, 2025

Participant flow

Participant flow — Overall Study
MilestoneRobotic-assisted PCI With Corpath GRX® SystemStandard PCI
Started10
Completed00
Not completed10

Outcome measures

PrimaryEvidence of Full Ostial Coverage at Angiographic and IVUS Assessment

Procedure-dependent geographic miss in millimeters (mm) obtained using intravascular ultrasound (IVUS)

Time frame:
Measured at end of procedure

No measurements were reported for this outcome.

SecondaryDistance From Most Proximal Stent Strut and Coronary Ostium (mm), as Assessed by IVUS

Distance from most proximal stent strut and coronary ostium (mm), as assessed by IVUS

Time frame:
Measured at end of procedure

No measurements were reported for this outcome.

SecondaryComparison of Participants With In-hospital Major Cardiovascular Events
Time frame:
Measured at discharge or 72 hours, whichever comes first
Reported as:
Number · Adverse Events
Comparison of Participants With In-hospital Major Cardiovascular Events
Adverse EventsRobotic-assisted PCI With Corpath GRX® SystemStandard PCI
Comparison of Participants With In-hospital Major Cardiovascular Events0—
SecondaryProcedural Duration

Defined as the duration from when the sheath is inserted until it is removed

Time frame:
Measured at end of procedure
Reported as:
Number · minutes
Procedural Duration
minutesRobotic-assisted PCI With Corpath GRX® SystemStandard PCI
Procedural Duration75—
SecondaryMajor Adverse Cardiovascular Events at 1 Month Follow-up
Time frame:
Measured at 1 month

No measurements were reported for this outcome.

Adverse events

Collected over Adverse event data was ascertained on the the day of the one subject enrollment. After the subject was unable to undergo the study treatment per protocol the study was discontinued due to Sponsor business decision and therefore no additional adverse event data was collected.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Robotic-assisted PCI With Corpath GRX® System0/1 (0%)0/1 (0%)0/1 (0%)
Standard PCI———

Baseline characteristics

One subject was enrolled and randomized to Robotic-assisted PCI with Corpath GRX® System, however they were withdrawn before they could be treated with the CorPath GRX due to tortuous vessel anatomy. The study was then closed and no other subjects were enrolled.

Age, Customized
Age, Customized(Participants)Robotic-assisted PCI With Corpath GRX® SystemStandard PCITotal
Count of participants1—1
Sex: Female, Male
Sex: Female, Male(Participants)Robotic-assisted PCI With Corpath GRX® SystemStandard PCITotal
Female1—1
Male0—0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Robotic-assisted PCI With Corpath GRX® SystemStandard PCITotal
Hispanic or Latino0—0
Not Hispanic or Latino1—1
Unknown or Not Reported0—0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Robotic-assisted PCI With Corpath GRX® SystemStandard PCITotal
American Indian or Alaska Native0—0
Asian0—0
Native Hawaiian or Other Pacific Islander0—0
Black or African American0—0
White1—1
More than one race0—0
Unknown or Not Reported0—0
Region of Enrollment
Region of Enrollment(participants)Robotic-assisted PCI With Corpath GRX® SystemStandard PCITotal
Italy1—1
Canadian Cardiovascular Society (CCS) Angina Grade
Canadian Cardiovascular Society (CCS) Angina Grade(units on a scale)Robotic-assisted PCI With Corpath GRX® SystemStandard PCITotal
Number3—3
07

Study locations

1 site
  • Maria Cecilia Hospital
    Cotignola, RA 48033, Italy
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Nov 23, 2022

Documents are hosted by the registry — open the source record to download them.

09

Registry details

Key details

Study ID
NCT05634538
Lead sponsor
Corindus Inc.
Responsible party
Sponsor
First posted
Dec 2, 2022
Start date
Mar 30, 2023
Primary completion
May 8, 2023
Completion
May 8, 2023
Results posted
Jun 4, 2025
Last update
Jun 4, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion